Background Negative symptoms are a core aspect of psychopathology in schizophrenia.
Currently available pharmacological agents have proven minimally efficacious for …

Objective Findings on the efficacy of intranasal oxytocin (IN-OT) in schizophrenia have been
inconsistent. This meta-analysis of double-blind randomized controlled trials (RCTs) …

Schizophrenia is a heterogeneous disorder in which psychiatric symptoms are classified into
two general subgroups—positive and negative symptoms. Current antipsychotic drugs are …

Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth,
parturition and lactation. It has been implicated in the control of social behaviors and …

BACKGROUND: Both human and animal studies suggest oxytocin may have antipsychotic
properties. Therefore, we conducted a clinical trial to directly test this notion. METHODS …

Intranasal oxytocin (OT) has been suggested as a putative adjunctive treatment for patients
with schizophrenia and autism spectrum disorders (ASD). Here, we examine available …

BACKGROUND: Deficits in olfactory identification have been widely reported in patients with
schizophrenia (SZ) and are associated with negative symptomatology. Adjunctive oxytocin …

Introduction: In recent years, several studies were conducted to explore the potential
augmenting effect of oxytocin for the treatment of individuals with severe mental illness …

While there is growing interest in the potential for intranasal oxytocin (IN-OT) to improve
social cognition and neurocognition (ie, nonsocial cognition) in schizophrenia, the extant …

Background Impairment of oxytocinergic function and/or oxytocin receptor genetic
abnormalities has been demonstrated in patients with schizophrenia. Oxytocin reverses …